Compare ABM & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABM | SRPT |
|---|---|---|
| Founded | 1909 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.5B |
| IPO Year | 1994 | 2000 |
| Metric | ABM | SRPT |
|---|---|---|
| Price | $39.15 | $17.91 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 29 |
| Target Price | ★ $47.80 | $25.85 |
| AVG Volume (30 Days) | 323.3K | ★ 2.6M |
| Earning Date | 06-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.92% | N/A |
| EPS Growth | ★ 102.34 | N/A |
| EPS | 0.64 | ★ 2.88 |
| Revenue | ★ $8,745,900,000.00 | $2,198,237,000.00 |
| Revenue This Year | $5.97 | N/A |
| Revenue Next Year | $3.45 | N/A |
| P/E Ratio | $62.27 | ★ $5.99 |
| Revenue Growth | 4.62 | ★ 15.58 |
| 52 Week Low | $36.96 | $10.42 |
| 52 Week High | $52.94 | $43.92 |
| Indicator | ABM | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 43.56 | 43.95 |
| Support Level | $38.29 | $17.11 |
| Resistance Level | $41.17 | $18.10 |
| Average True Range (ATR) | 0.98 | 0.77 |
| MACD | -0.02 | -0.08 |
| Stochastic Oscillator | 39.35 | 32.79 |
ABM Industries Inc is a provider of integrated facility solutions. It offers its solutions through five segments: Business and Industry, Manufacturing and Distribution, Education, Aviation and Technical solutions. The company derives the majority of its revenue from the business and industry segment, which encompasses janitorial, facilities engineering, and parking services for commercial real estate properties and sports and entertainment venues, hospitals, as well as vehicle maintenance and other services to rental car providers. The company mainly operates in the United States of America.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.